MariTidevsSemaglutide

MariTide (maridebart cafraglutide) is a peptide-antibody conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody. This dual GLP-1 agonist + GIP antagonist mechanism is distinctive — most competing dual incretin drugs (tirzepatide, CT-388, VK2735) activate both receptors. The rationale for GIP antagonism is based on genetic and pharmacological evidence that loss-of-function in GIP signalling is associated with reduced obesity, suggesting that blocking rather than activating GIP may produce superior weight-loss outcomes.

The GLP-1 agonist component drives the established appetite-suppression and glycemic-control effects of the incretin pathway. The GIP receptor antagonist antibody simultaneously blocks GIP signalling at adipocytes and centrally, which preclinical data suggest enhances energy expenditure, reduces lipid storage, and amplifies the weight-loss effect of GLP-1 receptor activation. Whether GIP agonism (as in tirzepatide) or GIP antagonism (as in MariTide) is superior remains an open question that Phase 3 head-to-head data may eventually resolve.

The antibody-conjugated structure produces an exceptional pharmacokinetic profile, with a half-life of approximately three weeks. This supports once-monthly subcutaneous dosing — a unique practical advantage over the once-weekly schedules of all other late-stage obesity drugs. Phase 2 results showed roughly 20% body weight loss at 52 weeks. Animal studies have also suggested slower weight regain after discontinuation than seen with shorter-acting GLP-1 agonists, possibly due to the prolonged drug exposure during the washout period. Phase 3 MARITIME trials launched in 2026 will define the molecule's clinical positioning.

Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.

In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.

The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.